The effect of natriuretic peptides and bradykinin on development of brain oedema after ischemic stroke by Marina Dobrivojević et al.
MEETING ABSTRACT Open Access
The effect of natriuretic peptides and bradykinin
on development of brain oedema after ischemic
stroke
Marina Dobrivojević1,2, Katarina Špiranec2,3, Dunja Gorup1,2, Igor Erjavec4, Srećko Gajović1,2, Aleksandra Sinđić2,5*
From 7th International Conference on cGMP Generators, Effectors and Therapeutic Implications
Trier, Germany. 19-21 June 2015
Background
Ischemic stroke is characterized by a rapid loss of brain
function due to disturbance in blood supply to a part of
the brain. Due to fixed intracranial space, any increase
in intracranial fluid volume, or progressive brain oedema
formation, contributes to further deterioration of the
already impaired brain function. Bradykinin (BK), which
levels increase during ischemic stroke, promotes blood–
brain barrier permeability and raises intracranial capil-
lary blood pressure, leading to brain oedema formation.
Furthermore, BK induces glutamate release from neu-
rons and astrocytes via activation of BK receptor type 2.
suggesting involvement of BK in glutamate neurotoxi-
city. It has been recently shown that humans without
functional natriuretic peptides (NPs) suffer from massive
stokes [1,2].
NPs can reduce brain oedema and have a neuropro-
tective role in acute ischemic stroke as well as during
recovery after stroke. Although mechanisms are still not
clear, it appears that NPs enhance angiogenesis, neuro-
genesis and oligodenrogenesis [3,4]. One of the possible
beneficiary effects of NPs during the stroke could be an
inhibition of BK pathological function.
Materials and methods
Aim of our study is to determine beneficial effects of the
NPs in stroke development in murine model (middle
cerebral artery occlusion – MCAO). The symptoms of
the stroke are determined by behavioural studies. The
sizes of the lesion and brain oedema are established by
μCT. Furthermore, we determined the effects of NPs on
the BK signalling pathway in primary culture of neurons
and astrocytes using whole cell patch clamp experiments
to measure membrane potential and measurements of
intracellular Ca2+ concentration.
Results
In primary isolated astrocytes and neurons, BK binding
to type 2 receptor, leads to an increase in intracellular
C2+ concentration of astrocytes and neurons, followed
by activation of Ca2+-dependent Cl- channel which
depolarized the cell membrane. Agonists of guanylate
cyclase A, partially guanylate cyclase C but not guany-
late cyclase B inhibited the effects of BK at the mem-
brane potential and intracellular Ca2+ concentration via
regulators of G protein signalling. In vivo experiments
showed that urodilatin inhibited development of stroke
symptoms, the formation of the ischemic lesion and
brain oedema.
Conclusion
The results of this research show the existence of a nat-
ural antagonist of the BK receptor type 2 in the mouse
brain, and the possible use of NPs in treatment of the
stroke.
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